Please select the option that best describes you:
How do you anticipate rusfertide (VERIFY trial) will be used in the management of polycythemia vera?
Do you think it will become first-line therapy? Is potential iron overload a concern with long-term use?
Answer from: at Academic Institution
Rusfertide, an injectable hepcidin mimetic (1), is another new arrow in the quiver of 21st-century therapies for controlling erythropoiesis without phlebotomy in polycythemia vera (PV), though likely to be replaced in the near future by gene silencing technology, which does not require as frequent d...
Sign in or Register to read more